{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:20:19Z","timestamp":1777461619002,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.10.014","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T19:53:18Z","timestamp":1445802798000},"page":"6503-6510","source":"Crossref","is-referenced-by-count":12,"title":["Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5\u20137 May 2014"],"prefix":"10.1016","volume":"33","author":[{"given":"Nancy J.","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Hickling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guus F.","family":"Rimmelzwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda C.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Boslego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Rudenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Yeolekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin R.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.10.014_bib0365","first-page":"461","article-title":"Vaccines against influenza WHO position paper \u2013 November 2012","volume":"87","author":"WHO","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0370","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza virus infection in humans \u2013 on the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0375","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.vaccine.2013.06.047","article-title":"Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24\u201326 January 2013","volume":"31","author":"Girard","year":"2013","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.10.014_bib0380","first-page":"B5","article-title":"Decade of vaccine collaboration","volume":"31","author":"Global Vaccine Action Plan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0385","unstructured":"Global Action Plan for Influenza Vaccines (GAP): http:\/\/www.who.int\/influenza_vaccines_plan\/en\/ [accessed 03.03.15]."},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.014_bib0390","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.vaccine.2011.02.079","article-title":"WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer","volume":"29","author":"Friede","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0395","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.vaccine.2012.10.111","article-title":"Global production capacity of seasonal influenza vaccine in 2011","volume":"31","author":"Partridge","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0400","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jit207","article-title":"Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets","volume":"208","author":"Cheng","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0405","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/infdis\/jit294","article-title":"Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1","volume":"208","author":"Jegaskanda","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0410","doi-asserted-by":"crossref","first-page":"13706","DOI":"10.1128\/JVI.01666-13","article-title":"Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques","volume":"87","author":"Jegaskanda","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0415","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1128\/JVI.01219-14","article-title":"Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques","volume":"88","author":"Florek","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0420","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1469-0691.2011.03701.x","article-title":"Profiling of humoral immune responses to influenza viruses by using protein microarray","volume":"18","author":"Koopmans","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0425","doi-asserted-by":"crossref","first-page":"e54890","DOI":"10.1371\/journal.pone.0054890","article-title":"Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination","volume":"8","author":"Huijskens","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0430","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/infdis\/jit224","article-title":"Population-level antibody estimates to novel influenza A\/H7N9","volume":"208","author":"Boni","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0435","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2014.06.020","article-title":"Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots","volume":"61","author":"De Bruin","year":"2014","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0440","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jit207","article-title":"Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets","volume":"208","author":"Cheng","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0445","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0450","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0455","doi-asserted-by":"crossref","first-page":"14330","DOI":"10.1073\/pnas.1311998110","article-title":"Human circulating influenza-CD4+ ICOS1+IL-21+T cells expand after vaccination, exert helper function, and predict antibody responses","volume":"110","author":"Spensieri","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0460","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1016\/j.vaccine.2012.02.077","article-title":"Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach","volume":"30","author":"Wagner","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0465","unstructured":"Consortium for the Standardization of Influenza Seroepidemiology (CONSISE) website: https:\/\/consise.tghn.org\/ [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0470","unstructured":"UNISEC website. http:\/\/www.unisecconsortium.eu\/ [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0475","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.1128\/JVI.02133-14","article-title":"Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans","volume":"88","author":"Nachbagauer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0480","doi-asserted-by":"crossref","first-page":"200ra114","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0485","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.antiviral.2013.09.018","article-title":"Universal anti-neuraminidase antibody inhibiting all influenza A subtypes","volume":"100","author":"Doyle","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0490","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jis232","article-title":"A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection","volume":"205","author":"Giles","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0495","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0500","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-\u03b3 T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0505","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0510","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0515","doi-asserted-by":"crossref","first-page":"e94051","DOI":"10.1371\/journal.pone.0094051","article-title":"Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB\/c mice","volume":"9","author":"Chowdhury","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0520","unstructured":"Flugen Company website: www.flugen.com [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0525","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1016\/j.vaccine.2013.10.029","article-title":"A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine","volume":"31","author":"Kobayashi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0530","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaut.2014.07.005","article-title":"Epitope-based approaches to a universal influenza vaccine","volume":"54","author":"Gottlieb","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0535","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coviro.2014.02.008","article-title":"Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses","volume":"6C","author":"Jin","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0540","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.01.033","article-title":"Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants","volume":"50C","author":"Ahmed","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0550","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0140-6736(11)60174-8","article-title":"Cell-culture-derived influenza vaccine production","volume":"377","author":"Glezen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0555","doi-asserted-by":"crossref","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0560","series-title":"BARDA international and domestic capacity building activities","author":"Huebner","year":"2013"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0565","series-title":"Tables on clinical evaluation of influenza vaccines","author":"WHO","year":"2014"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0570","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok\u00ae) against influenza in healthy adults: a randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0575","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2014.08.003","article-title":"Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens","volume":"154","author":"Landry","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0580","unstructured":"Medicago. Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults. ClinicalTrials.gov Identifier: NCT01991587. http:\/\/clinicaltrials.gov\/show\/NCT01991587 [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0585","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant virus-like particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0590","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/adhm.201300006","article-title":"Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine","volume":"2","author":"Pearton","year":"2013","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0595","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-014-9565-z","article-title":"Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine","volume":"16","author":"Murugappan","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0600","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ejpb.2013.07.018","article-title":"Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants","volume":"85","author":"Murugappan","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0605","first-page":"11","article-title":"Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms","volume":"1","author":"Luke","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0610","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/infdis\/jit180","article-title":"Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect","volume":"208","author":"Ledgerwood","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0615","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1128\/JVI.03101-13","article-title":"Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model","volume":"88","author":"Price","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0620","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2471\/BLT.13.124412","article-title":"Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia","volume":"92","author":"Saha","year":"2014","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0625","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0630","unstructured":"PATH. Safety and immunogenicity of a single dose of intranasal seasonal trivalent live-attenuated influenza vaccine. ClinicalTrials.gov Identifier: NCT01625689. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01625689 [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0635","unstructured":"PATH. A randomized, controlled trial on the efficacy and safety of live-attenuated influenza vaccine (LAIV) among children in Bangladesh. ClinicalTrials.gov Identifier: NCT01797029. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01797029 [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0640","unstructured":"PATH. Clinical efficacy of trivalent live-attenuated influenza vaccine (LAIV) among children in Senegal. ClinicalTrials.gov Identifier: NCT01854632. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01854632 [accessed 03.03.15]."},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.10.014_bib0645","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2011.04.119","article-title":"A pandemic influenza vaccine in India: from strain to sale within 12 months","volume":"29","author":"Dhere","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0650","unstructured":"Biodiem Company website. http:\/\/www.biodiem.com\/laiv\/ [accessed 03.03.15]."},{"key":"10.1016\/j.vaccine.2015.10.014_bib0655","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00630-14","article-title":"Continuing reassortment leads to the genetic diversity of Influenza H7N9 in Guangdong China","author":"Lu","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0660","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature12379","article-title":"Biological features of novel avian influenza A (H7N9) virus","volume":"499","author":"Zhou","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0665","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0140-6736(13)61207-6","article-title":"Human infection with avian influenza A H7N9 virus: an assessment of clinical severity","volume":"382","author":"Yu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0670","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00100-14","article-title":"Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets","author":"Chen","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0675","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1016\/j.vaccine.2013.08.040","article-title":"H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus","volume":"31","author":"Rudenko","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0680","doi-asserted-by":"crossref","first-page":"e87962","DOI":"10.1371\/journal.pone.0087962","article-title":"Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine","volume":"9","author":"Rudenko","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0685","doi-asserted-by":"crossref","first-page":"185ra68","DOI":"10.1126\/scitranslmed.3006368","article-title":"Synthetic generation of influenza vaccine viruses for rapid response to pandemics","volume":"5","author":"Dormitzer","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0690","doi-asserted-by":"crossref","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0695","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1586\/14760584.2013.850036","article-title":"The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines","volume":"12","author":"Krammer","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0700","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00272-14","article-title":"An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans","author":"Krammer","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0705","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1016\/j.vaccine.2013.06.055","article-title":"Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines","volume":"32","author":"Chit","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0710","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1215817","article-title":"Vaccine for prevention of mild and moderate-to-severe influenza in children","volume":"369","author":"Jain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0715","series-title":"Guideline on influenza vaccines \u2013 quality module","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2014"},{"key":"10.1016\/j.vaccine.2015.10.014_bib0720","unstructured":"WHO. Second WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses. http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/2nd_influenzamtg_geneva_may14\/en\/ [accessed 03.03.15]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T23:17:54Z","timestamp":1567293474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15014292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":72,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15014292"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}